Detailed clinical summaries and press releases are available directly from CRISPR Therapeutics and medical news sources like Drug Discovery News . If you'd like to dive deeper into the research:
ANGPTL3 is a protein that normally inhibits enzymes that clear lipids from the blood. By "turning off" this gene, the body can more effectively remove fats. ATHENA HEART 310
Unlike daily pills or bi-monthly injections, CTX310 aims for a durable, permanent solution by editing DNA directly: Detailed clinical summaries and press releases are available
Recent data from clinical studies, including updates as of late 2025, show significant efficacy in participants: Unlike daily pills or bi-monthly injections, CTX310 aims
Mean reductions of ~49%, with peak effects reaching 87% .
(often associated with ATHENA trial contexts in heart disease research) is an experimental in vivo CRISPR gene-editing therapy designed to provide a one-time treatment for cardiovascular disease risk factors. It specifically targets the ANGPTL3 gene in the liver to permanently lower high levels of triglycerides (TG) and "bad" LDL cholesterol. 💡 Key Trial Results (Phase 1)